Capricor Therapeutics CAPR Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$114.59M-9.1% | -$105.04M-28.1% | -$81.99M-17.2% | -$69.98M-27.1% | -$55.06M-36.1% | ||
| $2.02M+6.8% | $1.89M+7.2% | $1.76M+8.2% | $1.63M+8.6% | $1.5M+5.2% | ||
| $17.4M+2.6% | $16.97M+10.0% | $15.42M+14.4% | $13.48M+12.5% | $11.98M+22.7% | ||
| $1.59M-73.5% | $5.98M+9.3% | $5.48M+12.5% | $4.87M+49.3% | $3.26M+67.8% | ||
| $3.17M-22.6% | $4.09M+129% | $1.79M+386% | $367.58K+34.6% | $273.11K-40.5% | ||
| —— | —— | —— | —— | —— | ||
| -$92.63M-32.7% | -$69.81M-14.4% | -$61.04M-15.2% | -$52.99M-17.3% | -$45.16M-12.9% | ||
| $7.13M+145% | $2.9M+68.0% | $1.73M+2.8% | $1.68M+15.6% | $1.45M+24.6% | ||
| -$81.05M-183% | $97.48M+241% | -$68.99M+16.8% | -$82.94M-0.2% | -$82.79M+28.7% | ||
| $238.45M+0.6% | $237.03M+193% | $80.92M-45.4% | $148.12M-1.3% | $150.08M-1.5% | ||
| $250.31M+0.6% | $248.89M+207% | $81.16M-45.3% | $148.48M-1.4% | $150.53M-1.5% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$59.83K+99.4% | -$10.31M— | —— | —— | —— | ||
| $1.59M-73.5% | $5.98M+9.3% | $5.48M+12.5% | $4.87M+49.3% | $3.26M+67.8% | ||
| $3.17M-22.6% | $4.09M+129% | $1.79M+386% | $367.58K+34.6% | $273.11K-40.5% | ||
| $1.37M+92.0% | $715.46K+119% | $327.27K+639% | -$60.75K-12.5% | -$54.01K-14.3% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $257.46K— | ||
| $17.4M+2.6% | $16.97M+10.0% | $15.42M+14.4% | $13.48M+12.5% | $11.98M+22.7% | ||
| —— | —— | —— | —— | —— | ||
| $1.06M+177% | $383.54K-39.1% | $629.46K-6.2% | $670.82K+19.6% | $560.65K+50.7% | ||
| —— | $3.05M+33.3% | $2.28M+50.0% | $1.52M+100% | $761.43K— | ||
| -$99.76M-37.2% | -$72.72M-15.8% | -$62.77M-14.8% | -$54.68M-17.3% | -$46.62M-13.2% | ||
| -$99.76M-37.2% | -$72.72M-15.8% | -$62.77M-14.8% | -$54.68M-17.3% | -$46.62M-13.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Capricor Therapeutics generate?
- Capricor Therapeutics (CAPR) generated -$92.6M in operating cash flow over the trailing twelve months.
- What is Capricor Therapeutics's free cash flow?
- After $7.1M of capital expenditures, Capricor Therapeutics's free cash flow was -$99.8M over the trailing twelve months, down 114.0% year over year.
- Where does Capricor Therapeutics's cash flow data come from?
- Every line is extracted from Capricor Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.